

Closing of Non-Renounceable Rights Issue

30 April 2009, Melbourne, Australia: Benitec Limited (ASX: BLT) advises that the non-renounceable rights issue has now been closed. The Company will make an announcement of any under subscriptions and the total number of new shares and new free attaching options that are issued under the offer in accordance with the offer timetable.

CONTACT:

BENITEC LTD

Sue MacLeman
Chief Executive Officer
+61 437 211 200

About Benitec

Benitec is an Australian biotechnology company focused on licensing its extensive intellectual property portfolio and developing therapeutics to treat serious diseases using its proprietary ddRNAi technology. Its current therapeutic program is focused on Human Immunodeficiency Virus (HIV). For additional information, please visit www.benitec.com.